A retrospective, observational, multicenter, cohort study assessing Effectiveness of Dolutegravir-based antiretroviral therapy in a real-world setting in HIV patients
Latest Information Update: 17 Apr 2020
Price :
$35 *
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 13 Apr 2020 Results published in the AIDS
- 24 Jan 2020 New trial record